Loading…

SolventumSOLVCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical/Nursing Services

Diversified healthcare company (spun off from 3M in 2024) making medical-surgical supplies, dental products, health information systems and purification/filtration technologies.

Momentum strong 67
Mkt cap
$14.7B
US dollars, full cap
Free float
85%
of shares outstanding
$/day
$111M
20-day average traded
Fwd P/E
11.7×
forward earnings
ROIC−WACC
-2.3 pp
WACC 7.9%
Hurdle
n/a
no reverse DCF
Official | Implied
BBB / BBB+
agencies · bond market
Next earnings
106 days
4 Mar 2027
Close · USD$86.48
1D+0.5%
1W-2.4%
1M+0.1%
3M-2.4%
6M+13.6%
YTD+9.1%
1Y+13.5%
ATR %3.1%
Beta0.62
52w lowhigh8.2% off high

What Solventum does

Diversified healthcare company (spun off from 3M in 2024) making medical-surgical supplies, dental products, health information systems and purification/filtration technologies.

Mostly sells consumables reordered through hospital supply contracts and dental distributors, with the coding software licensed and renewed each year, so much of the revenue repeats. It agreed in 2025 to sell its purification and filtration unit to Thermo Fisher, narrowing it to health care.

Products and services

  • MedSurg (wound care, infection prevention)
  • Dental Solutions
  • Health Information Systems (coding/software)
  • Purification & Filtration

Customers

  • Hospitals
  • Dentists/dental labs
  • Health systems (coding/software)
  • Industrial/biopharma purification customers

Where it sits in the supply chain

  • Healthcare
  • Diversified medtech/healthcare products
  • Medsurg, dental, health IT…

What could go right

  • Standalone strategic focus post-3M spinoff
  • Health IT/coding software growth

What could go wrong

  • High spinoff-related debt load
  • Legacy 3M-related litigation exposure

Moat: narrow (installed base, brand, switching costs). Inherited 3M's established medsurg/dental product lines and hospital/dentist relationships, now standalone.

Headquarters: Maplewood, Minnesota, USA · Founded: 2024 · Employees: 20,000

Named competitors

Solventum at a glance

Size Solventum (SOLV) is a United States Health Care company (Medical/Nursing Services) with a market value of $14.7B, the 601st largest of 3,085 United States companies the cockpit tracks. Shares closed at $86.48 on 18 Nov 2026.

Performance Over six months the shares gained 13.6%, against +16.9% for the median peer and -2.2% for the United States market (cap-weighted) — 8th lowest of 17 in its peer set.

Growth Revenue fell 3.1% over the last twelve months (peer median +11.8%); the operating margin is 8.4% (peer median 9.6%).

Valuation It trades at 11.7× forward earnings against a peer median of 21.3× (3rd cheapest of 16).

Capital Return on invested capital runs 2.3 points below its cost of capital (7.9% WACC).

Credit Solventum has 5 bonds outstanding ($4.92B), rated BBB by the agencies and trading like BBB+ at a weighted spread of 101 bp.

Short interest Short interest is 3.0% of the free float (30 Oct 2026).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

10011012021 May 202621 Aug 202618 Nov 2026Peer median 118SOLV 113
Six months, rebased to 100: Solventum against the median of its 17 peers (local-currency closes).

Solventum financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$8.16B$8.32B$8.25B$8.20B$8.13B
Revenue growth—+1%+1%+1%—
Gross profit$4.53B$4.46B$4.61B$4.69B$4.70B
EBITDA$1.18B$1.21B$1.63B$2.25B$2.27B
Net income$156M$1.56B$479M$1.35B$1.34B
Free cash flow$0-$10.0M$805M$1.62B$1.43B
Capital expenditure$310M$379M$380M$290M$251M
Total debt$5.27B$5.25B$8.18B$98.0M$95.0M

Quarterly statements and history in the cockpit →

Solventum competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%+75%-40%-20%0%+20%BTSGEHC300015FMEENSGDVAPHIALHRDNTCONLFSTOPCHBLLNHIMSMCOV-BSOLV6-month return →1-month return →
Up and to the right = strong over both horizons. Solventum is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%50×100×BTSGEHC300015FMEENSGDVAPHIASHLRDNTCONLFSTBLLNMCOV-BSOLVRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Solventum is the large dot.

Solventum competitors and peer comparison

Head to head with its named competitors (SOLV vs MMM vs BDX vs XRAY)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Solventum SOLV$14.7B+14%-3%8%11.7×n/a
3M MMM$93.6B+22%+2%21%18.8×11.3%
Becton Dickinson BDX$58.9B+48%-7%16%16.3×-1.6%
DENTSPLY SIRONA XRAY$1.69B-13%-1%5%6.8×11.2%

How Solventum compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Solventum against its 17 peers (data as of 18 Nov 2026)
MeasureSOLVPeer medianRank in peer set
1-month return+0.1%+7.2%6th lowest of 18
6-month return+13.6%+16.9%8th lowest of 17
Distance from 52-week high-8.2%-13.8%7th highest of 18
Revenue growth (TTM)-3.1%+11.8%lowest of 18
Operating margin8.4%9.6%7th lowest of 18
Forward P/E11.7×21.3×3rd cheapest of 16
ROIC minus cost of capital-2.3 pp+0.7 pp5th lowest of 18
EV / EBITDA16.6×13.9×5th most expensive of 14
Net debt / EBITDA4.1×2.7×5th most indebted of 17
Bond spread101 bp107 bp2nd tightest of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Solventum SOLVUnited States$14.7B+14%-3%8%11.7×n/an/a
BrightSpring Health Services BTSGUnited States$13.6B+17%+23%4%28.8×24.9%+18.3%
Encompass Health EHCUnited States$13.2B+27%+9%18%20.1×5.7%+5.0%
Aier Eye Hospital 300015.SZChina$12.5B-14%+5%21%30.1×11.8%+13.4%
Fresenius Medical Care FME.DEGermany$11.2B+3%-1%11%9.5×-4.8%+1.9%
Ensign ENSGUnited States$10.7B+3%+17%9%21.3×12.7%+16.5%
DaVita DVAUnited States$10.2B-18%+6%15%10.1×-2.5%+3.4%
Koninklijke Philips PHIA.ASNetherlands$29.0B+17%-1%10%16.4×5.9%+0.6%
Labcorp LHUnited States$30.1B+44%+6%11%19.3×14.5%0.0%
Sonic Healthcare SHL.AXAustralia$6.87B+6%+14%9%17.4×9.1%+3.5%
RadNet RDNTUnited States$5.66B+32%+21%5%93.2×38.8%+13.7%
Concentra Group Holdings Parent CONUnited States$5.31B+65%+12%17%22.3×3.6%+7.9%
Lifestance Health LFSTUnited States$5.24B+79%+23%6%51.8×33.4%+30.4%
Option Care Health OPCHUnited States$4.75B+43%+4%6%15.7×2.0%+13.2%
Fameglow 3774.HKHong Kong$4.54Bn/a+36%11%n/a57.4%+48.4%
BillionToOne BLLNUnited States$4.37B+7%+72%10%115.3×22.8%+71.9%
Hims & Hers Health HIMSUnited States$4.00B-26%+30%-1%n/an/an/a
Medicover MCOV-B.STSweden$3.87B+21%+3%7%36.1×19.6%+20.2%

Solventum bonds and credit

Solventum has 5 bonds outstanding with $4.92B face value. The agencies rate it BBB; its bonds trade like BBB+. Weighted yield 5.87%, a spread of 101 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Solventum's main competitors?
Named competitors: 3M (MMM), Becton Dickinson (BDX), Dentsply Sirona (XRAY). The cockpit's measured peer set (industry) also includes BrightSpring Health Services (BTSG), Encompass Health (EHC), Aier Eye Hospital (300015.SZ), Fresenius Medical Care (FME.DE), Ensign (ENSG), DaVita (DVA).
Is Solventum expensive compared with its peers?
On forward p/e it trades at 11.7× against a peer median of 21.3×, 3rd cheapest of 16 in its peer set.
How has Solventum stock performed?
Over six months to 18 Nov 2026 the shares returned +13.6% against +16.9% for the median peer; over one year +13.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.